Summary & Overview
CPT 81444: Genomic Sequence Analysis Panel for Solid Organ Neoplasms
CPT code 81444 represents a genomic sequence analysis panel for solid organ neoplasms, focusing on DNA analysis of 5 to 50 genes. This advanced laboratory procedure is pivotal in the molecular diagnosis and management of cancers affecting solid organs, such as the lung, breast, colon, prostate, and pancreas. The code is widely recognized in pathology and laboratory medicine, supporting the shift toward precision oncology and personalized treatment strategies.
Blue Cross Blue Shield is a key payer covering this service, reflecting its national relevance and adoption in clinical practice. Readers will gain insight into the clinical context of 81444, including its role in cancer diagnostics, typical laboratory settings, and its relationship to other molecular pathology codes. The publication also addresses policy updates, coding benchmarks, and the importance of accurate billing practices for genomic testing.
This summary provides a comprehensive overview of 81444, highlighting its significance in modern cancer care, payer coverage, and the evolving landscape of molecular diagnostics. Healthcare professionals, policy analysts, and laboratory administrators will find essential information to understand the scope and impact of this CPT code in pathology and laboratory medicine.
CPT Code Overview
CPT code 81444 is used for genomic sequence analysis panels targeting solid organ neoplasms. This procedure involves DNA analysis of 5 to 50 genes, providing critical molecular insights for the diagnosis and management of cancer in solid organs. The service is classified under Pathology and Laboratory, and is typically performed in a laboratory setting (Place of Service 81). This code supports precision medicine by enabling comprehensive genetic profiling, which can inform treatment decisions and improve patient outcomes.
Clinical & Coding Specifications
Clinical Context
A patient with a confirmed diagnosis of a solid organ malignancy, such as lung, breast, colon, prostate, or pancreatic cancer, is referred for advanced molecular testing. The treating physician requests a genomic sequence analysis panel to evaluate the tumor's DNA for mutations across 5-50 genes. This information assists in guiding targeted therapy decisions and prognosis. The specimen is sent to a laboratory (Place of Service 81), where a pathologist or molecular genetic specialist performs the analysis and interprets the results for the clinical team.
Coding Specifications
-
Modifiers:
- Modifier
26: Used when reporting only the professional component (interpretation of results) of the procedure. - Modifier
TC: Used when reporting only the technical component (performance of the test) of the procedure. - Modifier
59: Used to indicate a distinct procedural service, typically when multiple procedures are performed on the same day.
- Modifier
-
Provider Taxonomies:
| Taxonomy Code | Specialty Name |
|---|